# Cytosorbents Q3 2026 Earnings Breakthrough

> Cytosorbents achieves first positive operating cash flow in Q3 2026 with 75% gross margins and German market rebound plans.
- Title: Cytosorbents Q3 2026 Earnings Breakthrough · The Motley Fool
- Summary: Cytosorbents achieves first positive operating cash flow in Q3 2026 with 75% gross margins and German market rebound plans.
- Keywords: cytosorbents, q3 2026, operating cash flow, german market, drugorb-atr, hemodefend-bga, nasdaq listing, de novo submission, blood filtration, medical device, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/13/cytosorbents-ctso-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-13T06:39:13+00:00
- Read time: 2 min
- Topics: cytosorbents, q3 2026, operating cash flow, german market, drugorb-atr, hemodefend-bga, nasdaq listing, de novo submission, blood filtration, medical device, finance, money
## Q3 Revenue Milestone
Cytosorbents reported $9.7 million Q3 revenue, a 3% year-over-year increase driven by distributor and strategic partner sales.
## Gross Margin Improvement
Product gross margin reached 75%, up 200 basis points from prior quarter due to manufacturing efficiencies and optimized material sourcing.
## Operating Expenses Down
Operating expenses declined 11% year over year to $8.5 million, reflecting headcount reductions and tighter cost controls.
## Adjusted EBITDA Loss Improvement
Adjusted EBITDA loss narrowed 86% to $0.3 million, driven by higher gross profit and leaner cost structure.
## Operating Cash Flow Breakthrough
Achieved first positive operating cash flow of $43,000 excluding restructuring payments, a key financial milestone.
## German Market Strategy
Hired Alex Tiefenbacher as Senior VP of Direct Sales to rebuild German market and strengthen international channels.
## German Revenue Decline
German revenue declined 20% to 21% year over year due to reduced sales force and territory coverage.
## DrugSorb-ATR Clinical Evidence
BARC-4 bleeding reduction of 37% in 587 patients, representing statistically significant improvement in cardiac surgery.
## De Novo Submission Prep
Preparing expanded evidence package for 250 patients to strengthen benefit-risk analysis for FDA De Novo submission.
## HemoDefend-BGA Funding
Received $16 million in non-dilutive U.S. government funding for universal blood filtration technology.
## Addressable Market Potential
Estimated $300 million to $2 billion addressable market for DrugSorb-ATR in U.S. and Canada.
## Nasdaq Listing Requirement
Working to satisfy remaining Nasdaq continued listing requirement and debt restructuring by end of 2026.
## Cash Position
Ended Q3 with $5.7 million cash and restricted cash, representing improved liquidity position.
## Inventory Reduction
Inventory reduced from $5.3 million at end of 2025 to $3.2 million by end of Q3 2026.
## Headcount Reduction
Reduced headcount by 24% since September 2025 through commercial restructuring and lean strategy.
## Next Steps
Targeting early 2027 De Novo submission for DrugSorb-ATR with expanded clinical evidence package.
## Key takeaway

Cytosorbents reported $9.7 million Q3 revenue with 75% gross margins, achieved first positive operating cash flow, and plans to rebuild German sales team by early 2027.